BioCentury | Aug 8, 2020
Product Development

Data sharing in and after COVID, with Takeda’s Anne Heatherington: a BioCentury podcast

Among the barriers broken by biopharmas during COVID-19 is the concept of data sharing, an idea far from standard practice in the industry, gaining life due to the gravity and urgency of the pandemic. Proponents...
BioCentury | Aug 8, 2020
Product Development

Novavax secures multicountry access to COVID-19 vaccine

Building on its commitment to make its COVID-19 vaccine globally accessible, Novavax closed two partnerships this week to supply Japan, India and lower income countries with doses of NVX-CoV2373. The biotech plans to start a...
BioCentury | Aug 8, 2020
Product Development

Bringing COVID-19 vaccines to authorization faster through data sharing

Developers of leading COVID-19 vaccines won’t be able to meet global demand on their own, but they do have the power to accelerate global coverage by helping each other reach authorization and streamlining development for...
BioCentury | Aug 7, 2020
Deals

Survey: sweet spots and vulnerabilities for dealmaking in the COVID era

Heading into the second half of the year with cautious optimism, drug developers see opportunities for dealmaking created by COVID-19, as well as challenges. If their predictions are right, infectious deals could surpass cancer transactions....
BioCentury | Aug 7, 2020
Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

With more than $1 billion in upfront money via its biggest deal yet, Denali now has enough firepower to bring its lead program into late-stage testing and validate its CNS delivery technology in the clinic....
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Inhibiting MAO-B or GABRA5 could treat subcortical stroke by restoring regional glucose metabolism and alleviating diaschisis, neurological dormancy at sites distant from a focal brain injury. In a rat model...
BioCentury | Jul 31, 2020
Deals

Sangamo’s latest deal brings in Novartis, includes autism

In its second neurology-focused deal of the year, and sixth with a large biopharma, Sangamo has partnered with Novartis to turn its zinc finger gene modulation technology toward neurodevelopmental disorders, such as autism and intellectual...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Inhibiting proteolytic activation of the receptor PAR2 for eosinophilic esophagitis

DISEASE CATEGORY: Inflammation INDICATION: Eosinophilic esophagitis Inhibiting the extracellular serine protease KLK5 or its substrate PAR2 could treat eosinophilic esophagitis, a food antigen-driven inflammatory disease. Single-cell sequencing revealed aberrant KLK5 expression in multiple cell populations...
BioCentury | Jul 22, 2020
Finance

Shonan iPark venture consortium seeks to boost bets on Japanese biotechs

A consortium established by Japanese life sciences accelerator Shonan iPark aims to grow the funding base for local biotechs by bolstering connections between investors. The Japan VC Consortium, launched Tuesday, will promote collaboration between Japanese...
Items per page:
1 - 10 of 3783